By Mill Chart
Last update: Dec 6, 2023
Uncover the potential of SANOFI-ADR (NASDAQ:SNY) as our stock screener's choice for an undervalued stock. NASDAQ:SNY maintains a strong financial position and offers an appealing valuation. We'll delve into the specifics below.
ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:SNY scores a 8 out of 10:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:SNY has achieved a 8:
A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:SNY has received a 7 out of 10:
ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:SNY was assigned a score of 5 for growth:
Our Decent Value screener lists more Decent Value stocks and is updated daily.
Our latest full fundamental report of SNY contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
SANOFI-ADR
NASDAQ:SNY (4/26/2024, 7:16:56 PM)
After market: 49.13 0 (0%)49.13
-0.23 (-0.47%)
/PRNewswire/ -- Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion...
SNY earnings call for the period ending March 31, 2024.
SNY stock results show that Sanofi beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade.
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Auddia stock is taking off on Monday with heavy trading of AUUD stock after the company received a new AI tech patent.
Apartment Income REIT stock is rising higher on Monday as investors in AIRC shares react to a deal to take the company private.
Sanofi layoffs are coming for the company's R&D employees and it makes major changes to how it handles development going forward.